tradingkey.logo

Transmedics Group Inc

TMDX
127.670USD
+6.600+5.45%
Close 12/19, 16:00ETQuotes delayed by 15 min
4.36BMarket Cap
47.17P/E TTM

Transmedics Group Inc

127.670
+6.600+5.45%

More Details of Transmedics Group Inc Company

TransMedics Group, Inc. is a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure. The Company specializes in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Its Organ Care System (OCS) is a portable organ perfusion, optimization and monitoring system that utilizes its customized technology to replicate near-physiologic conditions for donor organs outside the human body. It also developed its National OCS Program (NOP), which is a turnkey solution to provide outsourced organ procurement, OCS perfusion management and transplant logistics services, to provide transplant programs in the United States. Its logistics services include aviation transportation and other coordination activities. Its NOP provides trained organ procurement surgeons, clinical specialists and transplant coordinators that provide an end-to-end clinical solution using its OCS technology.

Transmedics Group Inc Info

Ticker SymbolTMDX
Company nameTransmedics Group Inc
IPO dateMay 02, 2019
CEOHassanein (Waleed H)
Number of employees728
Security typeOrdinary Share
Fiscal year-endMay 02
Address200 Minuteman Road
CityANDOVER
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code01810
Phone19785520900
Websitehttps://www.transmedics.com/
Ticker SymbolTMDX
IPO dateMay 02, 2019
CEOHassanein (Waleed H)

Company Executives of Transmedics Group Inc

Name
Name/Position
Position
Shareholding
Change
Dr. Waleed H. Hassanein, M.D.
Dr. Waleed H. Hassanein, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
481.61K
-8.98%
Mr. James R. Tobin
Mr. James R. Tobin
Independent Chairman of the Board
Independent Chairman of the Board
177.21K
+1.22%
Dr. David Weill, M.D.
Dr. David Weill, M.D.
Independent Director
Independent Director
12.13K
--
Mr. Nicholas (Nick) Corcoran
Mr. Nicholas (Nick) Corcoran
Senior Vice President - Supply Chain and Operations
Senior Vice President - Supply Chain and Operations
7.04K
-44.49%
Ms. Merilee Raines, CPA
Ms. Merilee Raines, CPA
Independent Director
Independent Director
4.06K
+110.86%
Ms. Stephanie Lovell
Ms. Stephanie Lovell
Independent Director
Independent Director
4.06K
+110.86%
Mr. Thomas James Gunderson
Mr. Thomas James Gunderson
Independent Director
Independent Director
4.06K
+110.86%
Mr. Gerardo Hernandez
Mr. Gerardo Hernandez
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
331.00
-97.93%
Mr. Anil Ranganath
Mr. Anil Ranganath
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
--
--
Mr. Edwin M. Kania, Jr.
Mr. Edwin M. Kania, Jr.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Waleed H. Hassanein, M.D.
Dr. Waleed H. Hassanein, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
481.61K
-8.98%
Mr. James R. Tobin
Mr. James R. Tobin
Independent Chairman of the Board
Independent Chairman of the Board
177.21K
+1.22%
Dr. David Weill, M.D.
Dr. David Weill, M.D.
Independent Director
Independent Director
12.13K
--
Mr. Nicholas (Nick) Corcoran
Mr. Nicholas (Nick) Corcoran
Senior Vice President - Supply Chain and Operations
Senior Vice President - Supply Chain and Operations
7.04K
-44.49%
Ms. Merilee Raines, CPA
Ms. Merilee Raines, CPA
Independent Director
Independent Director
4.06K
+110.86%
Ms. Stephanie Lovell
Ms. Stephanie Lovell
Independent Director
Independent Director
4.06K
+110.86%

Revenue Breakdown

Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
OCS Liver net revenue
116.11M
74.26%
OCS Heart net revenue
35.67M
22.81%
OCS Lung net revenue
4.58M
2.93%
By RegionUSD
Name
Revenue
Proportion
United States
152.19M
97.34%
All other countries
4.16M
2.66%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
OCS Liver net revenue
116.11M
74.26%
OCS Heart net revenue
35.67M
22.81%
OCS Lung net revenue
4.58M
2.93%

Shareholding Stats

Updated: Tue, Nov 25
Updated: Tue, Nov 25
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
13.86%
Fidelity Management & Research Company LLC
13.45%
The Vanguard Group, Inc.
10.53%
State Street Investment Management (US)
3.74%
Two Sigma Investments, LP
3.10%
Other
55.32%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
13.86%
Fidelity Management & Research Company LLC
13.45%
The Vanguard Group, Inc.
10.53%
State Street Investment Management (US)
3.74%
Two Sigma Investments, LP
3.10%
Other
55.32%
Shareholder Types
Shareholders
Proportion
Investment Advisor
71.86%
Investment Advisor/Hedge Fund
23.66%
Hedge Fund
7.08%
Research Firm
4.62%
Individual Investor
2.95%
Bank and Trust
2.15%
Pension Fund
1.35%
Sovereign Wealth Fund
0.18%
Insurance Company
0.10%

Institutional Shareholding

Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
762
37.62M
110.09%
-8.17M
2025Q2
746
42.27M
124.01%
-2.30M
2025Q1
751
42.32M
125.08%
-2.32M
2024Q4
728
40.09M
119.11%
-642.74K
2024Q3
673
39.30M
117.10%
+1.37M
2024Q2
615
36.53M
110.85%
-3.27M
2024Q1
544
37.44M
113.97%
-4.28M
2023Q4
512
38.18M
116.94%
-3.46M
2023Q3
482
38.42M
117.77%
-240.92K
2023Q2
462
35.43M
108.88%
-81.81K
View more

Shareholder Activity

Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
4.73M
13.87%
-97.24K
-2.02%
Jun 30, 2025
Fidelity Management & Research Company LLC
4.63M
13.57%
-32.85K
-0.71%
Jun 30, 2025
The Vanguard Group, Inc.
3.59M
10.53%
+21.12K
+0.59%
Jun 30, 2025
State Street Investment Management (US)
1.29M
3.78%
-17.52K
-1.34%
Jun 30, 2025
Two Sigma Investments, LP
692.64K
2.03%
+666.54K
+2554.00%
Jun 30, 2025
Nomura Investment Management Business Trust
952.11K
2.79%
-163.49K
-14.66%
Jun 30, 2025
Geode Capital Management, L.L.C.
804.65K
2.36%
+11.24K
+1.42%
Jun 30, 2025
Driehaus Capital Management, LLC
854.04K
2.51%
+75.28K
+9.67%
Jun 30, 2025
Hood River Capital Management LLC
679.85K
1.99%
-115.92K
-14.57%
Jun 30, 2025
Emerald Advisers LLC
694.97K
2.04%
-22.39K
-3.12%
Jun 30, 2025
View more

Related ETFs

Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Global X HealthTech ETF
4.75%
Clough Select Equity ETF
2.87%
Invesco S&P SmallCap Health Care ETF
2.75%
State Street SPDR S&P Health Care Equipment ETF
2.18%
Invesco S&P SmallCap 600 Pure Growth ETF
1.54%
First Trust Nasdaq Lux Digi Health Solutions ETF
1.47%
iShares S&P Small-Cap 600 Growth ETF
0.63%
State Street SPDR S&P 600 Small Cap Growth ETF
0.61%
First Trust Multi-Manager Small Cap Opportunities ETF
0.58%
Vanguard S&P Small-Cap 600 Growth Index Fund
0.58%
View more
Global X HealthTech ETF
Proportion4.75%
Clough Select Equity ETF
Proportion2.87%
Invesco S&P SmallCap Health Care ETF
Proportion2.75%
State Street SPDR S&P Health Care Equipment ETF
Proportion2.18%
Invesco S&P SmallCap 600 Pure Growth ETF
Proportion1.54%
First Trust Nasdaq Lux Digi Health Solutions ETF
Proportion1.47%
iShares S&P Small-Cap 600 Growth ETF
Proportion0.63%
State Street SPDR S&P 600 Small Cap Growth ETF
Proportion0.61%
First Trust Multi-Manager Small Cap Opportunities ETF
Proportion0.58%
Vanguard S&P Small-Cap 600 Growth Index Fund
Proportion0.58%

Dividend

A total of 0.00 USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data

Stock Split

Date
Type
Ratio
No Data
Date
Type
Ratio
No Data

FAQs

Who are the top five shareholders of Transmedics Group Inc?

The top five shareholders of Transmedics Group Inc are:
BlackRock Institutional Trust Company, N.A. holds 4.73M shares, accounting for 13.87% of the total shares.
Fidelity Management & Research Company LLC holds 4.63M shares, accounting for 13.57% of the total shares.
The Vanguard Group, Inc. holds 3.59M shares, accounting for 10.53% of the total shares.
State Street Investment Management (US) holds 1.29M shares, accounting for 3.78% of the total shares.
Two Sigma Investments, LP holds 692.64K shares, accounting for 2.03% of the total shares.

What are the top three shareholder types of Transmedics Group Inc?

The top three shareholder types of Transmedics Group Inc are:
BlackRock Institutional Trust Company, N.A.
Fidelity Management & Research Company LLC
The Vanguard Group, Inc.

How many institutions hold shares of Transmedics Group Inc (TMDX)?

As of 2025Q3, 762 institutions hold shares of Transmedics Group Inc, with a combined market value of approximately 37.62M, accounting for 110.09% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -13.93%.

What is the biggest source of revenue for Transmedics Group Inc?

In FY2025Q2, the OCS Liver net revenue business generated the highest revenue for Transmedics Group Inc, amounting to 116.11M and accounting for 74.26% of total revenue.
KeyAI